Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Change in Account Payables (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Change in Account Payables for 2 consecutive years, with -$850019.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 515.31% to -$850019.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$838328.0 through Dec 2025, changed N/A year-over-year, with the annual reading at -$917663.0 for FY2025, 214.08% down from the prior year.
  • Change in Account Payables for Q4 2025 was -$850019.0 at Neuphoria Therapeutics, down from $216359.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $580663.0 in Q2 2025, with the low at -$917668.0 in Q3 2024.